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Abstract
Background: Hp
2 alleles of the haptoglobin a–chain polymorphism reduce the anti-oxidant properties and increase the pro-
inflammatory actions of this acute-phase protein in a gene-dosage fashion. We hypothesized that the haptoglobin
polymorphism might contribute to the increased oxidative stress and low-grade chronic inflammation frequently associated
with polycystic ovary syndrome, obesity, and abnormalities of glucose tolerance.
Methodology/Principal Findings: Serum haptoglobin and the haptoglobin a–chain polymorphism were determined in 141
patients with polycystic ovary syndrome and 102 non-hyperandrogenic women. Of the whole group of 243 premenopausal
women, 117 were obese and 51 showed abnormal glucose tolerance. Although serum haptoglobin concentrations were
similar in PCOS patients and controls, the former presented with an increased frequency of Hp
2 alleles (62% vs. 52%,
P=0.023). Circulating haptoglobin levels increased with obesity (P,0.001), yet no association was found between obesity
and haptoglobin genotypes. No differences were observed in haptoglobin levels or genotype frequencies depending on
glucose tolerance. Fifty percent of the variation in serum haptoglobin concentrations was explained by the variability in
serum C-reactive protein concentrations, BMI, insulin sensitivity and haptoglobin genotypes.
Conclusions/Significance: Serum haptoglobin concentrations in premenopausal women are largely dependent on the
haptoglobin polymorphism and on the presence of obesity, with insulin resistance and chronic inflammation possibly
modulating this relationship. The association of polycystic ovary syndrome with Hp
2 alleles suggests that the anti-oxidant
and anti-inflammatory properties of haptoglobin may be reduced in these patients.
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Introduction
Polycystic ovary syndrome (PCOS), a very prevalent syndrome
characterized by the association of hyperandrogenism with
chronic ovulatory dysfunction in premenopausal women [1,2], is
among the most common metabolic associations of both type 1
[3,4] and type 2 diabetes mellitus [5]. Hyperinsulinism and insulin
resistance are frequent findings in PCOS patients, and these traits
have cause-consequence relationships with obesity [6], increased
serum ferritin concentrations [7], low-grade chronic inflammation
[8], oxidative stress [9], and increased cardiovascular risk [10].
We have shown that serum ferritin concentrations are increased
in PCOS patients independently of chronic inflammation,
suggesting increased body iron stores in these women very
especially when obesity is also present [7]. Furthermore, our
recent results strongly suggest that insulin resistance and
hyperinsulinism, and not the reduced menstrual losses derived
from oligomenorrhea or mutations in the hemochromatosis HFE
gene, underlie the origin of these increased body iron stores
[11,12].
But iron metabolism is a complex system in which protection
against iron losses and against the oxidative damage caused by free
iron radicals are predominant mechanisms [13]. Haptoglobin, a
circulating acute-phase protein that is synthesized in the liver
under the influence of several cytokines such as TNF-a and
interleukin-6 [14], ameliorates the iron loss and renal injury that
follows the liberation of hemoglobin from erythrocytes during
processes of intravascular hemolysis. Haptoglobin accomplishes
this function by forming soluble complexes with hemoglobin,
thereby reducing the generation of oxygen reactive species and
ameliorating oxidative stress [14]. Also, haptoglobin inhibits the
synthesis of prostaglandins and the vasodilation mediated by nitric
oxide, and exerts immunomodulatory actions by its binding to the
CD163 receptor present in macrophages and monocytes [14].
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5606The molecular structure of haptoglobin is determined in humans
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2 [15] that may be explored by DNA genotyping or by
plasma gel electrophoresis phenotyping [14]. The Hp
2/Hp
2
genotype=Hp 2-2 phenotype reduces plasma haptoglobin levels,
decreases its hemoglobin-binding capacity and anti-oxidant prop-
erties and the secretion of anti-inflammatory cytokines such as IL-
10, while increasing immunological reactivity [16].
Furthermore, haptoglobin phenotypes influence serum ferritin
concentrations, and increased ferritin concentrations have been
described not only in PCOS, but also in insulin resistant disorders
such as obesity, type 2 diabetes mellitus and the metabolic
syndrome [13]. Men expressing the Hp 2-2 phenotype present
with increased serum ferritin concentrations when compared with
men expressing the Hp 2-1 and Hp 1-1 phenotypes [17].
Haptoglobin is expressed in adipocytes [18] and, because serum
haptoglobin concentrations correlate with increasing body weight,
its circulating concentrations are increasingly being considered as
a marker of adiposity. Finally, a recent proteomic analysis of serum
has identified both the a and b haptoglobin chains as potential
PCOS biomarkers [19,20].
Therefore, we conducted the present study hypothesizing that
haptoglobin and its polymorphism might mediate the associations
of PCOS with hyperferritinemia and increased body iron stores,
obesity and disorders of glucose tolerance.
Materials and Methods
Ethics statement
Written informed consent was obtained from all the participants
and the study was approved by the Clinical Research Ethics
Committee of Hospital Universitario Ramo ´n y Cajal.
Participants
We studied serum haptoglobin concentrations and haptoglobin
genotypes in a large series of obese and non-obese PCOS patients
and non-hyperandrogenic controls presenting with or without
abnormalities of glucose tolerance. The sample included 141 PCOS
patients and 102 non-hyperandrogenic Caucasian women prospec-
tively recruited at the Department of Endocrinology of Hospital
Universitario Ramo ´n y Cajal, a tertiary care academic hospital
affiliated with the University of Alcala ´. The diagnosis of PCOS
relied on the presence of oligo-ovulation and clinical and/or
biochemical hyperandrogenism, after excluding specific etiologies
[1,2,21]. The particular methods used to establish these criteria
have been reported earlier [6]. The non-hyperandrogenic control
group was composed of normal weight healthy female volunteers
and of consecutive overweight or obese women, who did not have
any known metabolic comorbidity, reporting to the clinical practice
of the authors solely for treatment of weight excess. Controls were
selected in order to be similar in terms of BMI with the patients.
None of the controls had signs or symptoms of hyperandrogenism,
menstrual dysfunction, or history of infertility.
According to their body mass index (BMI), women were
classified as being obese (BMI$30 kg/m
2) or non-obese
(BMI,30.0 kg/m
2), because only obesity - and not overweight -
has demonstrated a negative impact on mortality [22].
None of the participants had a personal history of hypertension,
regular alcohol consumption, disorders of glucose tolerance,
hyperuricemia, cardiovascular events, sleep apnea, or had received
treatment with oral contraceptives, antiandrogens or insulin
sensitizers for the previous 6 months.
Study protocol and assays
Clinical and anthropometrical variables, including the hirsutism
score, BMI and waist-to-hip ratio were determined as reported
previously [6]. Blood samples were obtained between days five and
10 of the menstrual cycle, or during amenorrhea after excluding
pregnancy, in all the participants. After a three-day 300-g
carbohydrate diet and 12-h overnight fasting, samples were
obtained early in the morning for the measurement of haptoglo-
bin, ferritin, C-reactive protein, total testosterone, sex hormone-
binding globulin and calculated free testosterone [23], andro-
stenedione, estradiol, dehydroepiandrosterone-sulfate, 17-hy-
droxyprogesterone, prolactin, thyrotropin, luteinizing hormone
and follicle-stimulating hormone. Complete serum biochemistry
and lipid profiles were also obtained. Then, a 75-g oral glucose
tolerance test was performed, and samples were obtained for
measurement of serum insulin and plasma glucose at 0, 30, 60, 90
and 120 min. Samples were immediately centrifuged, and serum
and plasma were separated and frozen at 230 C until assayed.
The circulating concentrations of haptoglobin were assayed by a
commercial immunonephelometry method (Dade Behring, Mar-
burg, Alemania) calibrated against the international CRM 470
reference material [24] with intraassay and interassay CV of 2.6%
and 6.2%, respectively. Haptoglobin genotypes were estimated
using the PCR-based technique previously described by Koch et al.
[25]. For plasma haptoglobin levels, we used the normal ranges
established internationally for each particular haptoglobin geno-
type/phenotype [14].
Serum ferritin and C-reactive protein concentrations were
measured by automated immunochemiluminescence (Immulite
2000 Ferritin and High Sensitivity CRP, Diagnostic Products
Corporation, Los Angeles, CA) with lower limit of detection of
0.88 pmol/l and 0.1 mg/l respectively, and intra- and inter-assay
coefficients of variation below 10%.
The technical characteristics of the assays employed for plasma
glucose concetrations, lipid profiles and serum hormone measure-
ments have been described elsewhere [6]. The composite insulin
sensitivity index was calculated from the circulating glucose and
insulin concentrations during the oral glucose tolerance test
according to Matsuda and DeFronzo [26], and women were
classified as having normal or abnormal glucose tolerance
(impaired fasting glucose, impaired glucose tolerance or diabetes)
according to the American Diabetes Association clinical practice
recommendations [27].
Statistical analysis
The results are reported as mean6standard deviation unless
otherwise stated. The association of the haptoglobin genomic
variants with PCOS, obesity and abnormalities of glucose
tolerance was explored using the x
2 or Fisher’s exact test as
appropriate. The Kolmogorov-Smirnov statistic was applied to
continuous variables. Logarithmic or square root transformations
were applied as needed to ensure normal distribution of the
variables, and parametric tests were applied thereafter. Mathe-
matical transformation was not applied to serum haptoglobin
levels, because this variable was normally distributed.
General linear models adjusting for age served to evaluate the
impact of PCOS on clinical and biochemical variables. General
linear models introducing the haptoglobin genotype, obesity and
glucose tolerance as independent variables, were used to study
their influence on phenotypic variables.
A multiple linear regression model with stepwise (probability of
F to enter#0.05, probability of F to remove$0.10) introduction of
age, BMI, waist-to-hip ratio, presence or absence of PCOS, serum
C-reactive protein, ferritin and free testosterone concentrations,
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2=2) as independent variables, was used
to evaluate the contribution of these variables to the variability in
serum haptoglobin concentrations. Analyses were performed using
SPSS10 for the Macintosh (SPSS Inc, Chicago, Illinois). P,0.05
was considered statistically significant.
Results
Comparison of clinical, biochemical and metabolic
variables among patients and controls
As expected by design the patients with PCOS and the non-
hyperandrogenic controls showed no statistically significant
differences in the mean BMI or in the distribution according to
the weight classification (Table 1), yet because PCOS patients
were younger than controls (25.466.3 vs 31.767.7 yr respectively,
P=0.001), age was introduced as a covariate in the following
analyses.
PCOS patients presented with increased hirsutism scores, waist-
to-hip ratio, fasting insulin and triglycerides, serum concentrations
of total and free testosterone, androstenedione, 17-hydroxypro-
gesterone, dehydroepiandrosterone-sulfate and luteinizing-hor-
mone (Table 2). On the contrary, the insulin sensitivity index as
well as serum sex hormone-binding globulin and estradiol levels
were reduced in the patients. Furthermore, there were no
differences in the frequency of smoking or of abnormal glucose
tolerance.
Haptoglobin and PCOS
Serum haptoglobin concentrations were not different among
PCOS patients and non-hyperandrogenic controls (Table 2).
Furthermore, the frequency of women presenting with serum
haptoglobin concentrations above the references values for their
haptoglobin genotype was similar in both groups (controls 25.5%
vs PCOS patients 26.1%, x
2=0.010, P=0.921).
After confirming that the haptoglobin genotype was distributed
according to Hardy-Weinberg equilibrium in both PCOS patients
and controls (data not shown), we found that the Hp
2 allele was
more frequent in the former (62% vs 52%, x
2=5.191, P=0.023),
explaining a borderline significant tendency towards a higher
frequency of Hp
2/Hp
2 genotype, and to a reduced frequency of the
Hp
1/Hp
1 genotype, in PCOS patients compared with the controls
(Table 3).
Finally, we confirmed that women with the Hp
2/Hp
2 genotype
had mildly reduced circulating haptoglobin concentrations





genotypes (Figure 1) yet the 10% difference in the frequencies of
haptoglobin genotypes among patients and controls, although
statistically significant, was not large enough to cause an actual
difference in their mean serum haptoglobin concentrations
(Table 2).
Haptoglobin and obesity
Serum haptoglobin levels were increased in obese women
irrespective of PCOS status (Figure 1). Accordingly, obese women
presented with a 5-fold increase in the frequency of women
presenting with elevated serum haptoglobin concentrations for
their haptoglobin genotype (non-obese 8.7%, obese women
44.1%, x
2=39.73, P,0.001).
Of note, the increase in serum haptoglobin concentrations with
obesity was unrelated to the haptoglobin polymorphism, because
its genotypes were equally distributed among non-obese and obese
women (Table 3).
Haptoglobin and abnormalities of glucose tolerance
Serum haptoglobin concentrations were not different when
women were classified according to their normal or abnormal
glucose tolerance (Figure 1), and the frequency of subjects
presenting with increased serum haptoglobin levels for their
genotype were not different depending on their glucose tolerance
(normal glucose tolerance 24.0%, abnormal glucose tolerance
33.3%, x
2=1.844 P=0.174). Finally, haptoglobin genotypes were
similarly distributed among the groups with normal or abnormal
glucose tolerance (Table 3).
Impact of the haptoglobin polymorphism, PCOS, obesity
and abnormalities of glucose tolerance on serum ferritin
and C-reactive protein concentrations
The haptoglobin genotype did not influence serum ferritin and
C-reactive protein concentrations (Figure 1). Serum ferritin
concentrations were higher in PCOS patients when compared
with non-hyperandrogenic controls (Table 2), were also higher in
obese women when compared with non-obese women (Figure 1),
and increased in the women presenting with abnormal glucose
tolerance (Figure 1). On the contrary, serum C-reactive protein
concentrations increased in obese women compared to their non-
obese counterparts and tended to increase (P=0.079) in the
women presenting with abnormal glucose tolerance (Figure 1), but
were similar in PCOS and non-hyperandrogenic women (Table 2).
Determinants of serum haptoglobin levels in
premenopausal women
A multiple regression model (R
2=0.498, F=58.6, P,0.0001)
demonstrated that 50% of the variation in serum haptoglobin
Table 1. Distribution of PCOS patients and controls according to their weight classification.
Weight classification *
Non-obese women (n=127) Obese women (n=118)
PCOS (n=141) n (%) 79 (56%) 62 (44%)
BMI (kg/m
2, mean6SD) 24.463.6 37.065.4
Controls (n=102) n (%) 47 (46%) 55 (54%)
BMI (kg/m
2, mean6SD) 24.664.2 36.965.4
*Women were classified into obese (BMI$30 kg/m
2) or non-obese (BMI,30.0 kg/m
2) subgroups according to their BMI.
No differences were observed between PCOS patients and controls in the distribution according to their weight classification (x




PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5606concentrations was explained by the variation in serum C-reactive
protein concentrations (b=0.405, P,0.001), BMI (b=0.251,
P,0.001), Hp genotypes (b=20.207, P,0.001) and insulin
sensitivity index (b=20.167, P=0.001). Age, PCOS, waist-to-
hip ratio, ferritin and free testosterone concentrations were
excluded by the stepwise regression model.
Table 2. Clinical and biochemical characteristics of PCOS patients and non-hyperandrogenic control women.
PCOS patients (n=141) Controls (n=102) P value
Body mass index (kg/m
2)3 0 6 83 1 6 8 0.483
Smokers (n, %) 44 32 34 33 0.843
Waist-to-hip ratio 0.784 6 0.081 0.784 6 0.078 0.015
Hirsutism score 10.0 6 6.1 1.5 6 1.7 0.001
Haptoglobin (g/l) 1.4 6 0.5 1.5 6 0.5 0.990
C-reactive protein (mg/l) 3.4 6 4.2 3.7 6 4.6 0.639
Ferritin (pmol/l) 121 6 101 79 6 46 0.001
Total testosterone (nmol/l) 2.2 6 0.9 1.4 6 0.5 0.001
Free testosterone (pmol/l) 45 6 23 22 6 9 0.001
Sex hormone-binding globulin (nmol/l) 32 6 17 45 6 23 0.001
17-hydroxyprogesterone (nmol/l) 2.9 6 1.6 1.9 6 1.1 0.001
Androstenedione (nmol/l) 13.3 6 5.0 8.3 6 3.0 0.001
Dehydroepiandrosterone-sulfate (mmol/l) 6.0 6 2.5 4.2 6 2.1 0.001
Luteinizing hormone (IU/l) 6.5 6 3.9 5.1 6 3.1 0.040
Follicle-stimulating hormone (IU/l) 6.0 6 4.4 6.1 6 4.3 0.487
Estradiol (pmol/l) 154 6 108 236 6 215 0.002
Cholesterol (mmol/l) 4.4 6 0.9 4.7 6 1.0 0.705
High-density lipoprotein cholesterol (mmol/l) 1.3 6 0.5 1.3 6 0.4 0.416
Low-density lipoprotein cholesterol (mmol/l) 2.6 6 0.8 2.9 6 0.8 0.511
Triglycerides (mmol/l) 1.1 6 0.9 1.0 6 0.5 0.002
Fasting glucose (mmol/l) 5.0 6 0.5 5.1 6 0.5 0.510
Fasting insulin (pmol/l) 101 6 73 71 6 47 0.001
Insulin sensitivity index 4.3 6 2.9 5.9 6 3.9 0.001
Normal glucose tolerance (n, %) 113 80 79 77 0.635
Abnormal glucose tolerance (n, %) 28 20 23 23
Results are means6SD or raw numbers and percentages. Continuous variables were submitted to a general linear model in which age was introduced as a covariate to
correct for the difference in age observed between patients and controls. Categorical variables were submitted to Fisher’s exact test.
doi:10.1371/journal.pone.0005606.t002




1 n( % ) Hp
2/Hp
1 n( % ) Hp
2/Hp
2 n( % )
Whole population (n=243) 48 (20) 107 (44) 88 (36)
PCOS patients (n=141) 22 (16) 61 (43) 58 (41)
Controls (n=102) 26 (26) 46 (45) 30 (29)
Non-obese women (n=126) 24 (19) 56 (44) 46 (37)
Obese women (n=117) 24 (20) 51 (44) 42 (36)
Normal glucose tolerance (n=192) 42 (22) 82 (43) 68 (35)
Abnormal glucose tolerance (n=51) 6 (12) 25 (49) 20 (39)
There was a borderline significant tendency towards an increased frequency of Hp
2/Hp
2 genotype, and a decreased frequency of the Hp
1/Hp
1 genotype, in PCOS
patients compared with non-hyperandrogenic controls (x
2=5.220, P=0.074 overall; x
2=3.650, P=0.056 for a dominant model; x
2=3.521, P=0.061 for a recessive
model).
There were no statistically significant differences in the distribution of haptoglobin genotypes among the women classified according to their weight classification
(x




PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5606Figure 1. Serum haptoglobin, C-reactive protein and ferritin concentrations as a function of the haptoglobin genotype, obesity and
glucose tolerance. Data are means and 95% confidence intervals. The numbers below the x-axis are the number of subjects in each subgroup.
*P,0.05 or less between haptoglobin genotypes; {P,0.05 or less between obese and non-obese women. {P,0.05 or less between women with
normal or abnormal glucose tolerance.
doi:10.1371/journal.pone.0005606.g001
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To our best knowledge, we here present the first data regarding
serum haptoglobin concentrations and its genotypes in patients
with PCOS. The most important finding of our present study is
that, compared with non-hyperandrogenic women, PCOS pa-
tients presented with an increased frequency of the Hp
2 allele (and




The importance of the association of PCOS with Hp
2 alleles is
that this polymorphism influences the functional properties of
haptoglobin in a way that might contribute to the known
clustering of cardiovascular risk factors in PCOS patients [10]
even in the absence of actual differences in serum haptoglobin
levels.
On the one hand, the haptoglobin polymorphism causes a gene-
dosage effect resulting in a graded decrease in the haptoglobin
ability to bind hemoglobin, in the antioxidant capacity and in
prostaglandin inhibition, with the Hp
2/Hp
2 genotype expressing
the weakest protein activities [14]. On the other hand, the
haptoglobin polymorphism also results in a graded increase in the
angiogenic and inflammatory effects of haptoglobin, with the Hp
2/
Hp
2 genotype expressing the strongest properties [14]. Therefore,
the increased frequency of Hp
2 alleles in our PCOS patients might
also play a role in the previously reported low-grade chronic
inflammation [28] and increased oxidative stress [9] of these
women, even when serum haptoglobin concentrations were not
altered in these PCOS women.
Supporting a role for the haptoglobin polymorphism in the
development of atherosclerotic disease and cardiovascular events,
the Hp 2-2 phenotype increases the risk for micro- and
macrovascular complications in diabetic patients [29] possibly
because this phenotype facilitates the generation of reactive
oxygen species, and oxidative stress is involved in myocardial
damage and atherosclerosis. Furthermore, in the ApoE knock-out
murine model of atherosclerosis, Hp
2/Hp
2 mice obtained by
targeted insertion of a murine type 2 Hp allele into the Hp locus by
homologous recombination show increased iron deposition, lipid
peroxidation and macrophage accumulation within atherosclerotic
plaque, increasing the risk of rupture and thrombosis [30].
Interestingly, PCOS patients show early markers of atherosclerosis
such as increased carotid intima-media thickness and coronary
artery calcification from young ages [31,32].
Of note, the difference in the frequency of haptoglobin
genotypes was actually caused by a relatively low frequency of
Hp
2 alleles in the controls when compared to that found in the
general population of other countries whereas, on the contrary, the
frequency found in the patients was similar to that reported in
other Caucasians populations.
This surprising finding has two possible explanations: first, the
frequencies of haptoglobin alleles in the Spanish population has
not been established, and may be lower compared with those
found in other European controls. Second, our controls were
selected as to have no known metabolic or hyperandrogenic
disorder, and considering the high prevalences of these conditions
in the general population, this selection bias may explain a
reduced frequency of Hp
2 alleles in them. Nevertheless, the
distribution of Hp alleles was in Hardy-Weimberg equilibrium in
both PCOS patients and in controls, ruling out significant
population stratification in our series.
The a chain haptoglobin polymorphism influences circulating
haptoglobin concentrations to a lesser degree compared with its
impact on the functionality of the protein [14]. This may explain
why PCOS patients, despite carrying Hp
2 alleles more frequently
than controls, did not have reduced serum haptoglobin levels.
Also, the lowering effect on serum haptoglobin levels of carrying
Hp
2 alleles may have been obscured in the PCOS patients
presented here because these women were insulin resistant
compared with the controls, and insulin resistance actually
increases serum haptoglobin levels [33] as our data also
demonstrate.
Our present results do not suggest that the haptoglobin
polymorphism influences the increased serum ferritin concentra-
tions of PCOS patients, in sharp contrast with the findings in male
hemochromatosis patients, in whom the Hp 2-2 phenotype
increases iron overload and the expression of the hemochromatosis
phenotype [17]. Although the ferritin lowering effect of regular
menstrual iron losses [34] might contribute to explain this
discrepancy, most of the PCOS patients had chronic oligomen-
orrhea, and our previous studies on PCOS patients suggest that
insulin resistance, and not genetic factors, is one of the major
determinants of increased serum ferritin concentrations and iron
stores in these women [12]. Similarly, the haptoglobin polymor-
phism did not influence serum C-reactive protein concentrations
in our population, yet the possible effect of the polymorphism on
local inflammatory mechanisms may have been obscured by the
strongest influence of obesity on the serum levels of this
inflammatory marker [35].
The impact of weight excess on serum haptoglobin concentra-
tions and the other circulating inflammatory markers studied here
merits further comment. Our present results indicate that serum
haptoglobin concentration, and the number of women presenting
with serum levels above the upper limit of the normal range,
increase with obesity. These results confirm the previously
reported association of circulating haptoglobin concentrations
with BMI [18,36], which might be dependent on the expression of
haptoglobin in adipose tissue [18]. Furthermore, obesity also
increases serum C-reactive protein and ferritin concentrations
pointing to the existence of chronic inflammation and increased
body iron stores in obesity and other disorders characterized by
the presence of insulin resistance.
Even when serum haptoglobin levels increase with insulin
resistance and obesity [18,33,36], neither serum haptoglobin levels
nor the haptoglobin genotype were related to the development of
disorders of glucose tolerance in our series of young premeno-
pausal women. Therefore, haptoglobin does not appear to be
involved in the failure of compensatory endogenous hyperinsulin-
ism to maintain glycemia within the normal range, which is the
hallmark of abnormal glucose tolerance in insulin resistant
subjects. On the contrary, increased body iron stores may have
contributed to this failure [13], because serum ferritin levels were
clearly increased in the women who had abnormal glucose
tolerance in our series. Of note, chronic inflammation might play a
similar role, yet the tendency towards an increase in serum C-
reactive protein levels in women presenting with abnormal glucose
tolerance did not reach statistical significance.
Our study was limited, however, by a relatively low statistical
power for detection of differences between the small subgroups
resulting from categorization by presence or absence of metabolic
traits. This limitation was especially evident when considering
glucose tolerance, and therefore a possible influence of haptoglo-
bin levels or genotypes on the development of disorders of glucose
tolerance cannot be definitely excluded by our present results.
Finally, the results of the multiple regression model indicates
that serum haptoglobin concentrations are determined in
premenopausal women by several factors including BMI, serum
C-reactive protein concentrations and the insulin sensitivity index,
in addition to haptoglobin genotypes. Overall, the result of the
Haptoglobin in Women
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5606regression analysis suggests that adipose tissue, and also the
chronic inflammatory milieu (possibly reflecting the action of
inflammatory cytokines such as TNF-a and IL-6 on the liver) and
the insulin resistant state associated with obesity, up-regulate
haptoglobin secretion contributing to its circulating concentra-
tions. On the contrary, the haptoglobin Hp
2/Hp
2 genotype
resulted in a mild decrease in serum haptoglobin concentrations
in our premenopausal women, as has been shown in other
populations [14].
In summary, the association of PCOS with Hp
2 alleles of
haptoglobin suggests that the functionality of this protein might be
altered in these women, even when its circulating concentrations
are not altered because their insulin resistance counteracts the
decrease in circulating haptoglobin usually associated with Hp
2
alleles. Also, our present results indicate that serum haptoglobin
levels of young premenopausal women are mostly dependent on
the haptoglobin polymorphism and on obesity, with insulin
resistance and chronic inflammation possibly contributing to this
association.
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